Navigation Links
Gene Variant Doubles Risk of Prostate Cancer in Black Men
Date:11/2/2007

expert thinks this study adds to an understanding of prostate cancer but has no immediate clinical application.

"It is encouraging that we are starting to identity some of these regions on the human genome that may be associated with an increased risk for prostate cancer," said Dr. Durado Brooks, director of prostate and colorectal cancer at the American Cancer Society. However, "it is unlikely that this is the only one," he added.

This variant doesn't seem to be associated with the aggressiveness of the disease, Brooks said. "It's important, but we are still a long way from having any strong clinical applicability from these findings," he said.

More information

For more on prostate cancer, visit the U.S. National Cancer Institute.



SOURCES: Rick Kittles, Ph.D., associate professor, medicine, University of Chicago; Durado Brooks, M.D., director, prostate and colorectal cancer, American Cancer Society, Atlanta; Oct. 31, 2007, Genome Research online


'/>"/>
Copyright©2007 ScoutNews,LLC.
All rights reserved  

0

GOOD

Page: 1 2

Related medicine news :

1. Gene variant foretells diabetic neuropathy
2. Gene Variants Linked to Early Heart Attack Discovered
3. Sugar variant may make a world of difference to Alzheimers disease
4. Striking a Gold Mine: H5N1 Vaccine may Serve as an Antidote for Mutants and Variants
5. Susceptibility Of TB In Humans Might Be Due To Three Human Gene Variants
6. Tougher Guidelines Needed To Prevent Variant Creutzfeldt-Jakob Disease
7. Gene variants hold clues about vulnerability to cardiovascular disease
8. Gene Variant associated with Schizophrenia identified
9. You may Live Long and Think Clear With a Variant Gene
10. Gene Variants Linked to Preterm Birth in Hispanic Women
11. Gene Variant Responsible for Acquiring Intellect and Memory in Humans Identified
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gene Variant Doubles Risk of Prostate Cancer in Black Men
Gene Variant Doubles Risk of Prostate Cancer in Black Men
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2